Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors [Yahoo! Finance]
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter [Yahoo! Finance]
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.